After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
The bond market has entered a financial twilight zone, and at this point, there doesn't seem to be a smooth way out.Market Insiderread more
Trump said he has "been thinking about payroll taxes for a long time" — and he cautioned that "whether or not we do something now, it's not being done because of recession."Politicsread more
Secretary of State Mike Pompeo privately told business executives and free traders that the trade war could end by the 2020 election and that hurdles to an immediate agreement...2020 Electionsread more
Market bull Jeff Saut told CNBC on Tuesday that the lows are in and the market is headed "much higher."Marketsread more
The company's stock seesawed after the markets closed Tuesday, initially swinging up by 4% before falling by about 2%.Retailread more
President Donald Trump believes he has quite the bargaining chip with the European Union.Marketsread more
The United States does not have a defense against hypersonic weapons, which can travel at least five times the speed of sound, or a little more than a mile per second....Defenseread more
See which stocks are posting big moves after the bell.Market Insiderread more
The Federal Reserve has lost control of interest rates as evidenced by the federal funds rate trading higher than any part of the U.S. Treasury yield curve, Jeffrey Gundlach,...Marketsread more
Some Apple employees have become disillusioned with the group's culture, where some have thrived while others feel sidelined.Technologyread more
estimates@ (Compares with estimates, adds share movement)
July 26 (Reuters) - Drugmaker AbbVie Inc on Friday raised its earnings forecast for the year and beat Wall Street estimates for second-quarter profit and revenue, as sales of its top-selling drug Humira did not fall as much as analysts had feared.
Shares of the Chicago-based company rose 2% to $68 before the bell.
Last month, AbbVie announced a $63 billion takeover deal for Botox-maker Allergan Plc, which it hopes will cushion the impact of biosimilar competition to Humira that treats rheumatoid arthritis and psoriasis. The drug has been under fire from cheap rivals in Europe and will face competition in the United States, it's biggest market, starting 2023.
Last year, Humira generated nearly $20 billion in revenue, while the world's second best-selling drug, Celgene Corp's Revlimid, brought in roughly half.
(For an interactive graphic on Humira sales, click here: https://tmsnrt.rs/2Mi1Mwm)
In the quarter ended June 30, biosimilar competition outside the United States caused overall Humira sales to slip about 6% to $4.87 billion, but it still beat the $4.80 billion forecast by five analysts polled by Refinitiv IBES.
U.S. sales for Humira rose 7.7% to $3.79 billion, but revenue outside the country slumped 35.2% to $1.08 billion.
Cancer drug Imbruvica, AbbVie's second-bestseller, brought in $1.10 billion, in line with expectations.
"This was a solid quarter for AbbVie," Edward Jones analyst Ashtyn Evans said. "We believe AbbVie's strong pipeline, which continued to progress well during the quarter, will make up for Humira sales declines."
For 2019, the company raised it adjusted earnings per share forecast to between $8.82 and $8.92 from a prior range of $8.73 to $8.83.
Net earnings in the reported quarter fell about 63% to $741 million, or 49 cents per share, as AbbVie recorded a $2.28 billion charge related to future payments associated with plaque psoriasis drug Skyrizi.
Skyrizi, on which the company has partnered with German drugmaker Boehringer Ingelheim, won U.S. approval in April and brought in sales of $48 million for AbbVie.
Excluding items, AbbVie earned $2.26 per share, beating estimates of $2.21.
Net revenue fell slightly to $8.26 billion from $8.28 billion, but handily beat the average analyst estimate of $8.10 billion.
(Reporting by Tamara Mathias and Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)